Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay-Reference-Cited by-同舟云学术

Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay

Published:2019-03-01 Issue:3 Volume:23 Page:358-362
ISSN:1027-3719
Container-title:The International Journal of Tuberculosis and Lung Disease
language:en
Short-container-title:int j tuberc lung dis

Author:

Berhanu R. H.¹,Schnippel K.²,Kularatne R.³,Firnhaber C.⁴,Jacobson K. R.⁵,Horsburgh C. R.⁶,Lippincott C.K.⁷

Affiliation:

1. Division of Infectious Diseases, University of North Carolina at Chapel Hill, North Carolina, USA, Department of Medicine, Faculty of Health Sciences, Health Economics and Epidemiology Research Office, University of the Witwatersrand, Johannesburg, Right to Care, Johannesburg

2. Right to Care, Johannesburg, Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences

3. National Institute for Communicable Diseases/National Health Laboratory Service and Department of Clinical Microbiology and Infectious Diseases, University of the Witwatersrand, Johannesburg, South Africa

4. Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences, Department of Medicine, Infectious Disease Division, University of Colorado, Denver, Colorado

5. Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts

6. Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts

7. Department of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA

Publisher

International Union Against Tuberculosis and Lung Disease

Subject

Infectious Diseases,Pulmonary and Respiratory Medicine

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breaking barriers: The potential of nanosystems in antituberculosis therapy;Bioactive Materials;2024-09

2. Assessing the quality of life in patients with drug-resistant tuberculosis: a cross-sectional study;BMC Pulmonary Medicine;2024-06-27

3. Factors influencing false-positive results of rifampicin resistance detected by Xpert MTB/RIF: A retrospective study in Zhejiang, China;Heliyon;2024-06

4. Discordance between genotypic and phenotypic methods for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis and the correlation with patient treatment outcomes;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-02

5. Financial burden of tuberculosis diagnosis and treatment for patients in Ethiopia: a systematic review and meta-analysis;BMC Public Health;2024-01-22